Follow-up study of Bastiaans LSD therapy
Investigators: Nicole Maalste, Hans Ossebaard Utrecht, Netherlands Contact: Sponsor: MAPS, Promind Foundation Retrospective survey study with former clients who were treated with drug therapy by Dr. Jan …
Request submitted to FDA to change the location of the treatment sessions
Request submitted to FDA to change the location of the treatment sessions from the Medical University of South Carolina (MUSC) to Dr. Mithoefer’s office. We propose renting a “crash cart” …
British Medical Journal: “Netherlands to Run Trials of Marijuana in Patients with Multiple Sclerosis”
The Dutch government has announced a small scale cross over trial into the effect of three sorts of medical marijuana, plus a placebo, on 16 patients with multiple sclerosis. Two foundations in Rotterdam, …
Differential Cognitive and Brain Activation Effects of the Isomers of MDE
Investigators: Dr. Spitzer, et al. University of Ulm, Germany Contact: This study was a double-blind, placebo-controlled investigation of the cognitive and brain activation effects of the isomers of MDE. …
After Two-Decade Halt, Marijuana Research Is Set
Comment from Rick Doblin: The article reports that medical marijuana research is about to begin for the first time in nearly two decades. However, the article makes a distinction that readers are not likely …
DEA Claims Application Was Lost
DEA claimed the application was lost. Prof. Craker resubmitted a photocopy but was told in February 2002 that the photocopied application was invalid since it didn’t have an original signature. In …
University of California at San Diego Gets Approval for Medical Marijuana Study
"University of California at San Diego Gets Approval for Medical Marijuana Study" A California university has received final approval from the federal government for a study on medical marijuana. …
The Fourth Patient in the Spain MDMA/PTSD Dose-response Study was Treated
The fourth patient in the Spain MDMA/PTSD dose-response study was treated on November 28, 2001. We have now completed the 50 mgs dose group (3 patients received 50 mgs and 1 received a placebo). The next …
FDA Contacted me to say that MAPS MDMA/PTSD Protocol was Approved
It’s my pleasure to report some excellent news. About 10 AM, Friday, November 2, FDA contacted me to say that MAPS’ MDMA/PTSD protocol was approved. This approval marks the culmination of 16 …
MDMA Research Update: October 2001
MAPS submitted to the FDA today the protocol for Dr. Michael Mithoefer and Dr. Mark Wagner’s MAPS-supported pilot study into the use of MDMA-assisted psychotherapy in the treatment of patients who …
Submission to FDA of a Protocol Designed to Study the Use of MDMA
As part of its submission to FDA of a protocol designed to study the use of MDMA in the treatment of PTSD, MAPS’ commissioned an extensive review of the scientific literature on MDMA. This literature …
A Draft of the MDMA/PTSD Protocol that MAPS has been Working for 2 Years to Develop
A draft of the MDMA/PTSD protocol that MAPS has been working for 2 years to develop, with Dr. Michael Mithoefer and Mark Wagner, Ph.D., at the Medical University of South Carolina, has now been posted …
